BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1044 related articles for article (PubMed ID: 23948895)

  • 1. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the pathological significance of tau oligomers?
    Cowan CM; Quraishe S; Mudher A
    Biochem Soc Trans; 2012 Aug; 40(4):693-7. PubMed ID: 22817718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
    Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
    J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From tau phosphorylation to tau aggregation: what about neuronal death?
    Buée L; Troquier L; Burnouf S; Belarbi K; Van der Jeugd A; Ahmed T; Fernandez-Gomez F; Caillierez R; Grosjean ME; Begard S; Barbot B; Demeyer D; Obriot H; Brion I; Buée-Scherrer V; Maurage CA; Balschun D; D'hooge R; Hamdane M; Blum D; Sergeant N
    Biochem Soc Trans; 2010 Aug; 38(4):967-72. PubMed ID: 20658986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Animal models of tauopathies].
    Higuchi M
    Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau oligomers as potential targets for early diagnosis of tauopathy.
    Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
    J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
    Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
    Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granular tau oligomers as intermediates of tau filaments.
    Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
    Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.
    Paquet D; Schmid B; Haass C
    Neurodegener Dis; 2010; 7(1-3):99-102. PubMed ID: 20173336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sources of extracellular tau and its signaling.
    Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
    J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic Localisation of Tau.
    Hanger DP; Goniotaki D; Noble W
    Adv Exp Med Biol; 2019; 1184():105-112. PubMed ID: 32096032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model.
    Marinković P; Blumenstock S; Goltstein PM; Korzhova V; Peters F; Knebl A; Herms J
    Brain; 2019 Apr; 142(4):1051-1062. PubMed ID: 30847469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.